Dear Colleagues



It is with great pleasure that we invite you to attend The Congress on Clinical Controversies in Lung Cancer (CCLC2018) which will take place 13-14 December 2018 in London, UK.

CCLC2018 will raise hot debates associated with the care of lung cancer including “wise” tissue analysis, complex gene analysis, the complexity of liquid biopsy, update of the current algorithm of lung cancer, targeted therapies and immunotherapy. 

We will also discuss the tough questions of should all patients get combo IO-Chemo? Should we really start with Alectinib for all ALK patients, how do we deal with brain disease, how do we reduce radiation toxicity and other “hands on” topics in lung cancer.

The Congress will welcome oncology professionals, lung cancer specialists, treatment experts, CRO’s, industry leaders and other experts to the majestic city of London.

The congress will focus on the following key areas:
Update in Locally Advanced Disease 
Tissue Analysis in the Era of Precision Cancer Care
Molecular Profiling and Predicting Biomarkers for ImmunoTherapy
Stage IA Lung Cancer 
Early Detection of Lung Cancer (Update & Biomarkers)
Brain Disease
Radiotherapy
Ethics

We hope you will join us at CCLC2018 in London.




Prof. Nir Peled, MD PhD FCCP

Congress Chair